% | $
Quotes you view appear here for quick access.

Teva Pharmaceutical Industries Limited Message Board

  • biohitechinvestor biohitechinvestor Feb 7, 2013 9:42 AM Flag

    The report was in line with expectations and dividend increase...

    I expect the company to take a more aggressive approach to increase revenue in the future...I believe the stock should end in the green today once investors realize the potential here. It's time this company starts growing again. Hopefully the new CEO will guide the company in that direction. I'm positive here. Comments?

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • elbit Feb 11, 2013 7:08 PM Flag

      I have enough spec stocks. TEVA is solid, pays a dividend, and will likely get out of the doldrums in time. I like having at least one stock in my portfolio that is not wildly manipulated, provides some income, and is more likely to grow than remain static.

    • Yes, I thought it was positive that they reaffirmed the year view. The stock was already pricing in a lower outlook IMO. I don't expect the stock to rocket upward, but maybe a bottom is in, and this can get back to better valuation with the help of that divvy.

      • 1 Reply to whbog
      • I believe the dividend increase was purposely held back in December and awarded today to try and take the spotlight off of a revenue and earnings miss. The miss (albeit small) is worse than it sounds. Remember, Levin had said in the second quarter that 3rd quarter earnings would be weak followed by a very strong 4th quarter. I would not call this a very strong quarter. As far as reaffirming 2013 guidance, so what? If you remember that was quite a haircut done on earnings at the time they lowered guidance. I would hope at this juncture this guy kinda knows what the heck he is talking about when providing guidance on earnings and revenue. The stock will continue to be dead money for the forseeable future. Unless they can pull a rabbit out of the hat there is no reason to own it. Plenty of better opportunities, good luck all.

    • Again with normalized eps around $5 and the stock trading at $38 I guess there is a good margin of safety at these levels. Management have got 3 years of time to get their act together and engineer a strategy to replace the waning of Copaxone. If they start showing some credibility and score some points in the future the stock should move

54.79-0.37(-0.67%)Jul 28 4:02 PMEDT